Allogene Therapeutics SEC filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic CAR T product candidates. The filings cover material-event reports, operating and financial updates, common stock registration and offering activity, and clinical disclosures involving programs such as cema-cel in large B-cell lymphoma and ALLO-329 in autoimmune disease.
Allogene's proxy materials describe annual meeting proposals, shareholder voting matters, board governance, executive compensation, and equity award disclosures. Other filings address Nasdaq-listed common stock, capital-structure changes, material agreements, and risk factors tied to research and development, clinical execution, regulatory matters, intellectual property, and licensed gene-editing technology used in its allogeneic CAR T programs.
Allogene Therapeutics, Inc. announced the commencement of a proposed underwritten public offering of its common stock. In connection with this new offering, the company has suspended sales of common stock under its existing at-the-market program conducted through a Sales Agreement with TD Securities (U.S.A.) LLC.
The company stated it will not sell shares under that Sales Agreement again unless and until it files a new prospectus or prospectus supplement with the SEC. Any sales related to the proposed offering will be made only through a written prospectus that meets Securities Act requirements.
Allogene Therapeutics reported interim results from its pivotal Phase 2 ALPHA3 trial of its allogeneic CAR T therapy cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma. In the first 24 randomized patients, 58.3% (7/12) in the cema-cel arm achieved minimal residual disease (MRD) negativity versus 16.7% (2/12) with observation, a 41.6 percentage-point difference in MRD clearance.
Plasma ctDNA levels at Day 45 fell by a median 97.7% from baseline with cema-cel, while the observation arm showed a 26.6% median increase. Cema-cel was generally well tolerated, with no treatment-related serious adverse events, and no reported cytokine release syndrome, ICANS, or graft-versus-host disease. Ten of 12 treated patients were managed fully as outpatients.
The ALPHA3 trial is enrolling about 220 high-risk patients across more than 60 sites and is powered to detect a 50% reduction in event-free survival risk. Allogene expects an interim EFS analysis in mid-2027 and a primary EFS analysis in mid-2028, which, if positive, could support a Biologics License Application for cema-cel.
Allogene Therapeutics SVP and Chief Technical Officer Benjamin Machinas Beneski reported a small sale of 2,867 shares of Common Stock at $2.50 per share. The company states this transaction was executed solely to cover tax withholding obligations tied to vesting restricted stock units under its equity incentive plan.
Following the sale, Beneski directly holds 195,338 shares of Allogene Therapeutics common stock. The filing explains the sale was a mandatory “sell to cover” transaction chosen by the company’s plan and is not a discretionary trade by the executive.
Allogene Therapeutics submitted a Form 144 notice for the proposed sale of 2,867 shares of Common Stock, filed 04/01/2026 through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares reflect the vesting of a restricted stock unit award dated 03/31/2026 granted under the issuer's equity compensation plan.
Allogene Therapeutics SVP and Chief Technical Officer Benjamin Beneski reported a small open-market sale of 4,835 shares of Common Stock at a weighted average price of $2.47 per share. The shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units under the company’s equity incentive plan and were required by a “sell to cover” election, meaning the transaction was not a discretionary trade. After this sale, Beneski directly holds 198,205 shares of Allogene common stock.
Allogene Therapeutics President and CEO David D. Chang reported an open‑market sale of 47,763 shares of common stock at $2.47 per share. According to the disclosure, the shares were sold solely to cover tax withholding obligations triggered by the vesting of restricted stock units, under a mandatory “sell to cover” feature of the company’s equity incentive plan, so this was not a discretionary trade. After the transaction, Chang directly holds 5,150,599 common shares, and additional shares are held indirectly through the RTC 2019 Trust, JEC 2019 Trust, and the Chang 2006 Family Trust.
Allogene Therapeutics filed a Form 144 reporting a proposed sale of 4,835 shares of Common Stock listed on NASDAQ. The filing shows a related vesting of a restricted stock unit award on 03/13/2026 granted under the issuer's equity compensation plan. The Form 144 entry is dated 03/16/2026.
Allogene Therapeutics reported a Form 144 notice for 47,763 shares of Common Stock related to the vesting of restricted stock units on 03/13/2026. The filing lists these shares as granted under the issuer's equity compensation plan and shows the transaction date as 03/13/2026.
Allogene Therapeutics, Inc. files its annual report as a clinical-stage company focused on off‑the‑shelf, allogeneic CAR T therapies for cancer and autoimmune disease. Its approach uses gene‑edited donor T cells and a proprietary Dagger® technology to improve persistence and limit rejection.
The company’s strategy centers on three core programs: cema‑cel for large B‑cell lymphoma in the pivotal Phase 2 ALPHA3 first‑line consolidation trial, ALLO‑316 for renal cell carcinoma with RMAT designation, and ALLO‑329 for systemic autoimmune diseases with multiple Fast Track designations. Interim ALPHA3 MRD data are planned for April 2026 and initial ALLO‑329 proof‑of‑concept data for June 2026. Allogene highlights substantial accumulated and expected future losses, heavy dependence on a few lead assets and partners, manufacturing and regulatory complexity, and significant competition from autologous CAR T and other novel therapies.
Allogene Therapeutics reported fourth quarter and full-year 2025 results and highlighted progress across its allogeneic CAR T pipeline. The pivotal Phase 2 ALPHA3 trial of cema-cel in large B-cell lymphoma is underway, with an interim futility analysis focused on MRD clearance and early safety planned for April 2026.
The Phase 1 RESOLUTION trial of ALLO-329 in autoimmune disease is enrolling, with proof-of-concept data expected in June 2026. The company ended Q4 2025 with $258.3 million in cash, cash equivalents and investments, guiding that its cash runway extends into the first quarter of 2028. Full-year 2025 net loss was $190.9 million, or $0.87 per share.